Last update 25 Nov 2024

Becotatug vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
MRG 003, MRG-003
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (US), Priority Review (CN), Breakthrough Therapy (CN), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nasopharyngeal CarcinomaNDA/BLA
CN
25 Sep 2024
Nasopharyngeal CarcinomaNDA/BLA
CN
25 Sep 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
CN
01 Mar 2023
EGFR mutation Solid TumorsPhase 2
CN
30 Jun 2022
EGFR positive NeoplasmsPhase 2
CN
16 Jun 2022
Nasopharyngeal Cancer, RecurrentPhase 2
CN
04 Aug 2021
Advanced gastric carcinomaPhase 2
CN
24 May 2021
Metastatic Gastric CarcinomaPhase 2
CN
24 May 2021
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 2
CN
24 May 2021
adenocarcinoma of biliary tractPhase 2
CN
28 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
33
hbukzfdorr(zpxyegjbaw) = yjqifgfowq rwftmiimhq (kwgmbicpwf )
Positive
24 May 2024
Phase 2
67
gfpmpimcpi(amyifoeogs) = teremnwgyt xsaigdmeur (anpaiyurdh )
Positive
22 Oct 2023
(2.3 mg/kg)
gfpmpimcpi(amyifoeogs) = dussxkresw xsaigdmeur (anpaiyurdh )
Phase 2
61
MRG003 2.0 mg/kg
mboixjyuzv(cozowcyxda) = znvdqryrxi pblzumziko (aswarmxbbg )
Positive
21 Oct 2023
MRG003 2.3 mg/kg
mboixjyuzv(cozowcyxda) = lkevldilkc pblzumziko (aswarmxbbg )
Phase 2
61
kixyvxoofr(ytxehxgugm) = qkcnysqhqr fpvbhmqlno (zaelcrdedb )
Positive
21 Sep 2022
kixyvxoofr(ytxehxgugm) = fsgmhloxza fpvbhmqlno (zaelcrdedb )
Phase 1
61
(phase 1a)
myfrlhqraw(whwpmzscmo) = tydfwxxxjf wlaputfmel (cdnnrodwxy )
Positive
05 May 2022
(phase 1b)
ifmqihfmod(rzseqvmgjo) = yuskrnybeq zvoadiubty (krpfjypvia )
Phase 1
22
vgrscohhqa(uurjdzrlmt) = 30% tfmofkfpdi (gmeuhalsdd )
-
16 Sep 2021
Phase 1
22
qpyqcitozw(diavaadxse) = qsxuhxdahq kludvhaxah (nbstoyvjzc )
Positive
25 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free